Infliximab  ||| S:0 E:11 ||| NNP
for  ||| S:11 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
treatment  ||| S:19 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
ulcerative  ||| S:32 E:43 ||| NNS
colitis  ||| S:43 E:51 ||| VBP
This  ||| S:51 E:56 ||| DT
paper  ||| S:56 E:62 ||| NN
presents  ||| S:62 E:71 ||| VBZ
a  ||| S:71 E:73 ||| DT
summary  ||| S:73 E:81 ||| NN
of  ||| S:81 E:84 ||| IN
the  ||| S:84 E:88 ||| DT
evidence  ||| S:88 E:97 ||| NN
review  ||| S:97 E:104 ||| NN
group  ||| S:104 E:110 ||| NN
( ||| S:110 E:111 ||| -LRB-
ERG ||| S:111 E:114 ||| NNP
)  ||| S:114 E:116 ||| -RRB-
report  ||| S:116 E:123 ||| NN
into  ||| S:123 E:128 ||| IN
the  ||| S:128 E:132 ||| DT
clinical  ||| S:132 E:141 ||| JJ
effectiveness  ||| S:141 E:155 ||| NN
and  ||| S:155 E:159 ||| CC
cost-effectiveness  ||| S:159 E:178 ||| JJ
of  ||| S:178 E:181 ||| IN
infliximab  ||| S:181 E:192 ||| NN
for  ||| S:192 E:196 ||| IN
moderately  ||| S:196 E:207 ||| RB
to  ||| S:207 E:210 ||| TO
severely  ||| S:210 E:219 ||| RB
active  ||| S:219 E:226 ||| JJ
ulcerative  ||| S:226 E:237 ||| JJ
colitis  ||| S:237 E:245 ||| NNS
( ||| S:245 E:246 ||| -LRB-
UC ||| S:246 E:248 ||| NNP
)  ||| S:248 E:250 ||| -RRB-
based  ||| S:250 E:256 ||| VBN
upon  ||| S:256 E:261 ||| IN
a  ||| S:261 E:263 ||| DT
review  ||| S:263 E:270 ||| NN
of  ||| S:270 E:273 ||| IN
the  ||| S:273 E:277 ||| DT
manufacturer ||| S:277 E:289 ||| NN
's  ||| S:289 E:292 ||| POS
submission  ||| S:292 E:303 ||| NN
to  ||| S:303 E:306 ||| TO
the  ||| S:306 E:310 ||| DT
National  ||| S:310 E:319 ||| NNP
Institute  ||| S:319 E:329 ||| NNP
for  ||| S:329 E:333 ||| IN
Health  ||| S:333 E:340 ||| NNP
and  ||| S:340 E:344 ||| CC
Clinical  ||| S:344 E:353 ||| NNP
Excellent  ||| S:353 E:363 ||| NNP
( ||| S:363 E:364 ||| -LRB-
NICE ||| S:364 E:368 ||| NNP
)  ||| S:368 E:370 ||| -RRB-
as  ||| S:370 E:373 ||| IN
part  ||| S:373 E:378 ||| NN
of  ||| S:378 E:381 ||| IN
the  ||| S:381 E:385 ||| DT
single  ||| S:385 E:392 ||| JJ
technology  ||| S:392 E:403 ||| NN
appraisal  ||| S:403 E:413 ||| NN
( ||| S:413 E:414 ||| -LRB-
STA ||| S:414 E:417 ||| NNP
)  ||| S:417 E:419 ||| -RRB-
process ||| S:419 E:426 ||| NN
.  ||| S:426 E:428 ||| .
The  ||| S:428 E:432 ||| DT
submission  ||| S:432 E:443 ||| NN
indicated  ||| S:443 E:453 ||| VBD
that  ||| S:453 E:458 ||| IN
the  ||| S:458 E:462 ||| DT
efficacy  ||| S:462 E:471 ||| NN
of  ||| S:471 E:474 ||| IN
infliximab  ||| S:474 E:485 ||| NNS
( ||| S:485 E:486 ||| -LRB-
5  ||| S:486 E:488 ||| CD
mg ||| S:488 E:490 ||| CD
/ ||| S:490 E:491 ||| CD
kg ||| S:491 E:493 ||| CD
)  ||| S:493 E:495 ||| -RRB-
had  ||| S:495 E:499 ||| VBD
been  ||| S:499 E:504 ||| VBN
demonstrated  ||| S:504 E:517 ||| VBN
in  ||| S:517 E:520 ||| IN
terms  ||| S:520 E:526 ||| NNS
of  ||| S:526 E:529 ||| IN
higher  ||| S:529 E:536 ||| JJR
response  ||| S:536 E:545 ||| NN
rates  ||| S:545 E:551 ||| NNS
and  ||| S:551 E:555 ||| CC
a  ||| S:555 E:557 ||| DT
sustained  ||| S:557 E:567 ||| JJ
response  ||| S:567 E:576 ||| NN
in  ||| S:576 E:579 ||| IN
health-related  ||| S:579 E:594 ||| JJ
quality  ||| S:594 E:602 ||| NN
of  ||| S:602 E:605 ||| IN
life ||| S:605 E:609 ||| NN
.  ||| S:609 E:611 ||| .
For  ||| S:611 E:615 ||| IN
the  ||| S:615 E:619 ||| DT
cost-effectiveness  ||| S:619 E:638 ||| JJ
analysis ||| S:638 E:646 ||| NN
,  ||| S:646 E:648 ||| ,
the  ||| S:648 E:652 ||| DT
manufacturer  ||| S:652 E:665 ||| NN
built  ||| S:665 E:671 ||| VBD
a  ||| S:671 E:673 ||| DT
Markov  ||| S:673 E:680 ||| JJ
model  ||| S:680 E:686 ||| NN
to  ||| S:686 E:689 ||| TO
compare  ||| S:689 E:697 ||| VB
infliximab  ||| S:697 E:708 ||| VBN
with  ||| S:708 E:713 ||| IN
standard  ||| S:713 E:722 ||| JJ
care ||| S:722 E:726 ||| NN
.  ||| S:726 E:728 ||| .
It  ||| S:728 E:731 ||| PRP
estimated  ||| S:731 E:741 ||| VBD
the  ||| S:741 E:745 ||| DT
incremental  ||| S:745 E:757 ||| JJ
cost  ||| S:757 E:762 ||| NN
per  ||| S:762 E:766 ||| IN
quality-adjusted  ||| S:766 E:783 ||| JJ
life-year  ||| S:783 E:793 ||| NN
( ||| S:793 E:794 ||| -LRB-
QALY ||| S:794 E:798 ||| NNP
)  ||| S:798 E:800 ||| -RRB-
gained  ||| S:800 E:807 ||| VBD
was  ||| S:807 E:811 ||| VBD
between  ||| S:811 E:819 ||| IN
25,044  ||| S:819 E:826 ||| CD
pounds  ||| S:826 E:833 ||| NNS
and  ||| S:833 E:837 ||| CC
33,866  ||| S:837 E:844 ||| CD
pounds  ||| S:844 E:851 ||| NNS
depending  ||| S:851 E:861 ||| VBG
on  ||| S:861 E:864 ||| IN
the  ||| S:864 E:868 ||| DT
strategy  ||| S:868 E:877 ||| NN
used ||| S:877 E:881 ||| VBN
.  ||| S:881 E:883 ||| .
The  ||| S:883 E:887 ||| DT
ERG  ||| S:887 E:891 ||| NNP
report  ||| S:891 E:898 ||| NN
generally  ||| S:898 E:908 ||| RB
agreed  ||| S:908 E:915 ||| VBN
with  ||| S:915 E:920 ||| IN
the  ||| S:920 E:924 ||| DT
evidence  ||| S:924 E:933 ||| NN
on  ||| S:933 E:936 ||| IN
effectiveness  ||| S:936 E:950 ||| NN
of  ||| S:950 E:953 ||| IN
infliximab  ||| S:953 E:964 ||| NN
for  ||| S:964 E:968 ||| IN
subacute  ||| S:968 E:977 ||| JJ
exacerbations  ||| S:977 E:991 ||| NN
of  ||| S:991 E:994 ||| IN
UC ||| S:994 E:996 ||| NNP
.  ||| S:996 E:998 ||| .
However ||| S:998 E:1005 ||| RB
,  ||| S:1005 E:1007 ||| ,
there  ||| S:1007 E:1013 ||| EX
were  ||| S:1013 E:1018 ||| VBD
several  ||| S:1018 E:1026 ||| JJ
areas  ||| S:1026 E:1032 ||| NNS
of  ||| S:1032 E:1035 ||| IN
uncertainty ||| S:1035 E:1046 ||| NN
,  ||| S:1046 E:1048 ||| ,
of  ||| S:1048 E:1051 ||| IN
which  ||| S:1051 E:1057 ||| WDT
the  ||| S:1057 E:1061 ||| DT
interpretation  ||| S:1061 E:1076 ||| NN
of  ||| S:1076 E:1079 ||| IN
the  ||| S:1079 E:1083 ||| DT
importance  ||| S:1083 E:1094 ||| NN
of  ||| S:1094 E:1097 ||| IN
the  ||| S:1097 E:1101 ||| DT
quality  ||| S:1101 E:1109 ||| NN
of  ||| S:1109 E:1112 ||| IN
life  ||| S:1112 E:1117 ||| NN
changes  ||| S:1117 E:1125 ||| NNS
in  ||| S:1125 E:1128 ||| IN
the  ||| S:1128 E:1132 ||| DT
subacute  ||| S:1132 E:1141 ||| JJ
situation  ||| S:1141 E:1151 ||| NN
and  ||| S:1151 E:1155 ||| CC
the  ||| S:1155 E:1159 ||| DT
assessment  ||| S:1159 E:1170 ||| NN
of  ||| S:1170 E:1173 ||| IN
the  ||| S:1173 E:1177 ||| DT
adequacy  ||| S:1177 E:1186 ||| NN
of  ||| S:1186 E:1189 ||| IN
the  ||| S:1189 E:1193 ||| DT
evidence  ||| S:1193 E:1202 ||| NN
of  ||| S:1202 E:1205 ||| IN
effectiveness  ||| S:1205 E:1219 ||| NN
of  ||| S:1219 E:1222 ||| IN
infliximab  ||| S:1222 E:1233 ||| NN
in  ||| S:1233 E:1236 ||| IN
the  ||| S:1236 E:1240 ||| DT
acute  ||| S:1240 E:1246 ||| JJ
hospital-based  ||| S:1246 E:1261 ||| JJ
situation  ||| S:1261 E:1271 ||| NN
were  ||| S:1271 E:1276 ||| VBD
considered  ||| S:1276 E:1287 ||| VBN
pre-eminent  ||| S:1287 E:1299 ||| JJ
by  ||| S:1299 E:1302 ||| IN
the  ||| S:1302 E:1306 ||| DT
ERG ||| S:1306 E:1309 ||| NNP
.  ||| S:1309 E:1311 ||| .
This  ||| S:1311 E:1316 ||| DT
challenged  ||| S:1316 E:1327 ||| VBN
the  ||| S:1327 E:1331 ||| DT
estimates  ||| S:1331 E:1341 ||| NNS
of  ||| S:1341 E:1344 ||| IN
cost-effectiveness  ||| S:1344 E:1363 ||| JJ
offered  ||| S:1363 E:1371 ||| VBN
and  ||| S:1371 E:1375 ||| CC
suggested  ||| S:1375 E:1385 ||| VBD
that  ||| S:1385 E:1390 ||| IN
there  ||| S:1390 E:1396 ||| EX
should  ||| S:1396 E:1403 ||| MD
be  ||| S:1403 E:1406 ||| VB
a  ||| S:1406 E:1408 ||| DT
separate  ||| S:1408 E:1417 ||| JJ
assessment  ||| S:1417 E:1428 ||| NN
of  ||| S:1428 E:1431 ||| IN
infliximab  ||| S:1431 E:1442 ||| NN
for  ||| S:1442 E:1446 ||| IN
acute  ||| S:1446 E:1452 ||| JJ
exacerbations  ||| S:1452 E:1466 ||| NN
of  ||| S:1466 E:1469 ||| IN
moderately  ||| S:1469 E:1480 ||| RB
to  ||| S:1480 E:1483 ||| TO
severely  ||| S:1483 E:1492 ||| RB
active  ||| S:1492 E:1499 ||| JJ
UC ||| S:1499 E:1501 ||| NNP
.  ||| S:1501 E:1503 ||| .
The  ||| S:1503 E:1507 ||| DT
summary  ||| S:1507 E:1515 ||| NN
of  ||| S:1515 E:1518 ||| IN
the  ||| S:1518 E:1522 ||| DT
NICE  ||| S:1522 E:1527 ||| NNP
guidance  ||| S:1527 E:1536 ||| VBD
issued  ||| S:1536 E:1543 ||| VBN
in  ||| S:1543 E:1546 ||| IN
April  ||| S:1546 E:1552 ||| NNP
2008  ||| S:1552 E:1557 ||| CD
as  ||| S:1557 E:1560 ||| IN
a  ||| S:1560 E:1562 ||| DT
result  ||| S:1562 E:1569 ||| NN
of  ||| S:1569 E:1572 ||| IN
the  ||| S:1572 E:1576 ||| DT
STA  ||| S:1576 E:1580 ||| NNP
states  ||| S:1580 E:1587 ||| NNS
that ||| S:1587 E:1591 ||| IN
:  ||| S:1591 E:1593 ||| :
infliximab  ||| S:1593 E:1604 ||| NN
is  ||| S:1604 E:1607 ||| VBZ
not  ||| S:1607 E:1611 ||| RB
recommended  ||| S:1611 E:1623 ||| VBN
for  ||| S:1623 E:1627 ||| IN
the  ||| S:1627 E:1631 ||| DT
treatment  ||| S:1631 E:1641 ||| NN
of  ||| S:1641 E:1644 ||| IN
subacute  ||| S:1644 E:1653 ||| JJ
manifestations  ||| S:1653 E:1668 ||| NNS
of  ||| S:1668 E:1671 ||| IN
moderately  ||| S:1671 E:1682 ||| RB
to  ||| S:1682 E:1685 ||| TO
severely  ||| S:1685 E:1694 ||| RB
active  ||| S:1694 E:1701 ||| JJ
UC ||| S:1701 E:1703 ||| NNP
.  ||| S:1703 E:1705 ||| .
